Biologic Therapy in Rare Eosinophil-Associated Disorders: Remaining Questions and Translational Research Opportunities
Paneez Khoury,Florence Roufosse,Fei Li Kuang,Steven J Ackerman,Praveen Akuthota,Bruce S Bochner,Mats W Johansson,Sameer K Mathur,Princess U Ogbogu,Lisa A Spencer,Michael E Wechsler,Nives Zimmermann,Amy D Klion,Steven Ackerman,Praveen Akuthota,Kyle Amber,Adrian Baatjes,Lila Bahadori,Peter Baudy,Lee Baylis,Bruce Bochner,Danica Brister,Lisa Brunet,Caroline Carpentier,Donna Carstens,Julien Catherine,Kevin Chevalier,Krishan Chhiba,Joan Cook-Mills,Gauthier Coussement,Judah Denburg,Nermin Diab,Matthew Drake,William Friend,Allison Fryer,Patricia Fulkerson,Glenn Furuta,Gail Gauvreau,Gerald Gleich,Jamie Goddard,Matthieu Groh,Nicholas Hogan,Elizabeth Jacobsen,Mats Johansson,Jean-Emmanuel Kahn,Sina Karimi,Paneez Khoury,Tae-Bum Kim,Hirohito Kita,Amy Klion,Anna Kovalszki,Fei Li Kuang,Justin Kwiatek,Ji-Hyang Lee,Kristin Leiferman,Francesca Levi-Schaffer,Jean-Pierre Llanos,Irina Maric,Joanne Masterson,Sameer Mathur,James Melhorn,Andrew Menzies-Gow,Mike Minnicozzi,Alexander Mok,Daphne Montizaan,Ariel Munitz,Luiza Nader,Princess Ogbogu,Olusola Oladipo,Thomas O'Riordan,Keith Orlandini,Calman Prussin,Marc Rothenberg,Florence Roufosse,Guo-Ping Shi,Yoshiki Shiraishi,Dagmar Simon,Hans-Uwe Simon,Steven Smith,Lisa Spencer,Shigeharu Ueki,Michael Wechsler,Peter Weller,Benjamin Wright,Nives Zimmermann,
DOI: https://doi.org/10.1093/jleuko/qiae051
2024-03-08
Journal of Leukocyte Biology
Abstract:Abstract Rare eosinophil-associated disorders (EADs), including hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis and eosinophilic gastrointestinal disorders, are a heterogeneous group of conditions characterized by blood and/or tissue hypereosinophilia and eosinophil-related clinical manifestations. Although the recent availability of biologic therapies that directly and indirectly target eosinophils has the potential to dramatically improve treatment options for all EADs, clinical trials addressing their safety and efficacy in rare EADs have been relatively few. Consequently, patient access to therapy is limited for many biologics, and the establishment of evidence-based treatment guidelines has been extremely difficult. In this regard, multicenter retrospective collaborative studies focusing on disease manifestations and treatment responses in rare EADs have provided invaluable data for physicians managing patients with these conditions and helped identify important questions for future translational research. During the Clinical Pre-Meeting Workshop held in association with the July 2023 biennial meeting of the International Eosinophil Society in Hamilton, Ontario, Canada, the successes and limitations of pivotal multicenter retrospective studies in EADs were summarized, and unmet needs regarding the establishment of guidelines for use of biologics in rare EADs were discussed. Key topics of interest included: 1) clinical outcome measures, 2) minimally invasive biomarkers of disease activity, 3) predictors of response to biologic agents, and 4) long-term safety of eosinophil depletion. Herein, we report a summary of these discussions, presenting a state-of-the-art overview of data currently available for each of these topics, the limitations of the data, and avenues for future data generation through implementation of multidisciplinary and multicenter studies.
immunology,cell biology,hematology